Authors: Dippel, EJ Kereiakes, DJ Tramuta, DA Broderick, TM Shimshak, TM Roth, EM Hattemer, CR Runyon, JP Whang, DD Schneider, JF Abbottsmith, CW

Citation: Ej. Dippel et al., Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management, CATHET C IN, 52(3), 2001, pp. 279-286

Authors: Runyon, JP

Citation: Jp. Runyon, Facilitated percutaneous coronary intervention: Validating the open arteryhypothesis, J INVAS CAR, 12, 2000, pp. 22B-26B

Authors: Kereiakes, DJ Runyon, JP Broderick, TM Shimshak, TM

Citation: Dj. Kereiakes et al., IIb's are not IIb's, AM J CARD, 85(8A), 2000, pp. 23C-31C

Authors: Kereiakes, DJ Obenchain, RL Barber, BL Smith, A McDonald, M Broderick, TM Runyon, JP Shimshak, TM Schneider, JF Hattemer, CR Roth, EM Whang, DD Cocks, D Abbottsmith, CW

Citation: Dj. Kereiakes et al., Abciximab provides cost-effective survival advantage in high-volume interventional practice, AM HEART J, 140(4), 2000, pp. 603-610

Authors: Buchholz, DB Byers, CC Hinterlong, SJ Huensch, GD Morrison, RL Nanke, TR Runyon, JP Yu, HC

Citation: Db. Buchholz et al., Broadband fiber access: A fiber-to-the-customer access architecture, BELL LABS T, 4(1), 1999, pp. 282-299

Authors: Kereiakes, DJ Broderick, TM Roth, EM Whang, D Shimshak, T Runyon, JP Hattemer, C Schneider, J Lacock, P Mueller, M Abbottsmith, CW

Citation: Dj. Kereiakes et al., Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention, AM J CARD, 84(4), 1999, pp. 391-395